Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PHASE

Financiado

Cerrado

A PHArmacogenomic study of Statins in the Elderly at risk for cardiovascular dis...

A PHArmacogenomic study of Statins in the Elderly at risk for cardiovascular disease Cardiovascular disease is the leading cause of death in industrialized countries. The prevention of cardiovascular disease is critically dependent on lipid lowering therapy, which includes the 3-hydroxymethyl-3-methylglutaryl coen... ver más

30/06/2012

Leiden University...

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

ACADEMISCH ZIEKENHUIS LEIDEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2012-06-30 No tenemos la información de la convocatoria

0% 76% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

Leiden University Medical Ce...

0.00€ | Lider

UNIVERSITY OF GLASGOW

N.D. | Participante

UCC

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PREDICTION-ADR Personalisation of tREatment In Cardiovascular disease throu... 4M€ Cerrado

CVGENES-AT-TARGET Exploitation of genomic variants affecting coronary artery d... 8M€ Cerrado

TRANSPORTERPGX Transporter pharmacogenomics the contribution of transport... 2M€ Cerrado

TransCard Translating disease to cardiovascular health 8M€ Cerrado

FIGHTINGDRUGFAILURE Priorities and Standards in Pharmacogenomic Research Opport... 3M€ Cerrado

Sex Dimorphism Molecular circuits of sex dimorphism in cardiometabolic trai... 173K€ Cerrado

Líder del proyecto

ACADEMISCH ZIEKENHUIS LEIDEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cardiovascular disease is the leading cause of death in industrialized countries. The prevention of cardiovascular disease is critically dependent on lipid lowering therapy, which includes the 3-hydroxymethyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins). Although statins are the most prescribed class of drugs worldwide, and therapy is generally associated with a reduction in risk for cardiovascular events by 20-30%, clinical response can be highly variable and adverse effects occur in a minority of patients. Recent research has provided evidence that in many cases, genetic variation contributes to this variable drug response. Research efforts should be made in analyzing the differences in genetic background to identify which genetic variation accounts for the variability in clinical response. Here we present a study that will establish in a large prospective randomized clinical trial with statin allocation which genetic variation is responsible for the variation in drug response. In 5804 participants of the PROspective Study of Pravastatin in the Elderly at risk (PROSPER) we will perform a genome-wide scan to assess the genetic variation responsible for variation in lowering low-density lipoprotein levels, in clinical outcome and for the occurrence of adverse effects. The unique character of the PROSPER study is that the study is randomized in three European countries, therefore all associations can be replicated in these countries. Positive associations will be confirmed in two comparable large clinical trials, the WOSCOPS and the CARE study. Cardiovascular pharmacogenomics will lead to improvements in the use of personalized therapy based on an individual’s genetic make-up. Non-responders or subjects who experience adverse effects will not be indicated for statin treatment when they are identified. This will increase the quality of life for many elderly people with polypharmacy and comorbidity and reduce costs for healthcare organizations.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores